

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

INSIDE INFORMATION – AGENCY AGREEMENT

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

On 22 December 2015 (after trading hours), Zhuhai Essex Medipharma entered into the Agency Agreement with the Licensors, pursuant to which the Licensors appointed Zhuhai Essex Medipharma as the exclusive agent for the distribution and marketing of the product known as Iodized Lecithin Capsules* (適麗順) in the Authorised Regions at the one-off licence fees in an aggregate amount of RMB20,000,000 (equivalent to approximately HK\$23,920,584).

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (“**SFO**”).

On 22 December 2015 (after trading hours), Essex Medipharma (Zhuhai) Company Limited* (珠海億勝醫藥有限公司) (“**Zhuhai Essex Medipharma**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (“**Company**”, and together with its subsidiaries referred as “**Group**”), entered into an agency agreement (“**Agency Agreement**”) with Tibet Linzhi Parkson Pharmaceutical Co., Ltd.* (西藏林芝百盛藥業有限公司) (“**Parkson Pharmaceutical**”) and Liaoning Wanxin Pharmaceutical Co., Ltd.* (遼寧萬鑫藥業有限公司) (“**Wanxin Pharmaceutical**”, together with Parkson Pharmaceutical, “**Licensors**”).

Pursuant to the Agency Agreement, the Licensors appointed Zhuhai Essex Medipharma as the exclusive agent for the distribution and marketing of the product known as Iodized Lecithin Capsules* (適麗順) in the People's Republic of China (excluding, for the purpose of the Agency Agreement, the Liaoning Province, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan) (“**Authorised Regions**”) at the one-off licence fees in an aggregate amount of RMB20,000,000 (equivalent to approximately HK\$23,920,584) (“**Appointment**”). As none of the applicable ratios for the Appointment exceeds 5%, the Appointment does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

Subject to renewal or early termination pursuant to the terms of the Agency Agreement, the Appointment is valid for a period of 7 years commencing from 1 January 2016 to 31 December 2022.

The Group is principally engaged in the manufacturing, selling, marketing and distribution of biopharmaceutical products. Wanxin Pharmaceutical is wholly owned by Parkson Pharmaceutical and the Licensors are principally engaged in the manufacturing, research and development of medicines. Iodized Lecithin Capsules* (適麗順) has been approved in 2010 by China Food and Drug Administration (CFDA) for treating central serous chorioretinopathy, central exudative chorioretinopathy, vitreous haemorrhage, vitreous opacities and central retinal vein occlusion, etc.

The Appointment will expand the Group's ophthalmic product line into treating ocular fundus diseases and thus enhancing the Group's market foothold in the ophthalmology business.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 22 December 2015

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.

* *For identification purposes only*